Drug intelligence / Profile preview

Q-Derp1

Development stage: Preclinical
Lead developer: Kuros Biosciences
Modality: Recombinant Proteins and Enzymes
Administration: Sublingual

Overview

Q-Derp1 is an immunodrug developed by Cytos Biotechnology as an antigen for the prevention of various major chronic diseases. It appears to be based on Der p 1, which is a major allergen from the house dust mite Dermatophagoides pteronyssinus. Der p 1 is a papain-like cysteine protease that plays a significant role in allergic sensitization and symptoms.

Targets

BCR (Immunoglobulin G B Cell Receptor)TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on Q-Derp1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q-Derp1.

Explore the full profile